Safety and efficacy of dexmedetomidine hydrochloride combined with midazolam in fiberoptic bronchoscopy in children: a prospective randomized controlled study
ZHANG Jin, LIU Jie-Bo, ZENG Fen-Na, REN Qiao, LIN Hui-Ling, JIAN Li-Li, LIU Guo-Le
Department of Pediatrics, Shenzhen Luohu People's Hospital, Shenzhen, Guangdong 518000, China (Liu J-B, Email: jieboliu@hotmail.com)
Abstract：Objective To study the safety and efficacy of dexmedetomidine hydrochloride combined with midazolam in fiberoptic bronchoscopy in children. Methods A total of 118 children who planned to undergo fiberoptic bronchoscopy from September 2018 to February 2021 were enrolled. They were divided into a control group (n=60) and an observation group (n=58) using a random number table. The observation group received intravenous pumping of dexmedetomidine hydrochloride (2 μg/mL) at 1 μg/kg and then intravenous injection of midazolam at 0.05 mg/kg, followed by dexmedetomidine hydrochloride pumped intravenously at 0.5-0.7 μg/(kg·h) 10 minutes later to maintain anesthesia. The control group was given intravenous pumping of propofol at 2 mg/kg and then intravenous injection of midazolam at 0.05 mg/kg, followed by propofol pumped intravenously at 4-6 mg/(kg·h) 10 minutes later to maintain anesthesia. Fiberoptic bronchoscopy was performed after the children were unconscious. Heart rate (HR), respiratory rate, blood oxygen saturation, and mean arterial pressure (MAP) were recorded before inserting the bronchoscope (T0), at the time of inserting the bronchoscope (T1), when the bronchoscope reached the glottis (T2), when the bronchoscope reached the carina (T3), and when the bronchoscope entered the bronchus (T4). The intraoperative peak airway pressure (Ppeak), examination time, degree of sedation, extent of amnesia, incidence of adverse reactions, postoperative awakening time, and postoperative agitation score were also recorded. Results Compared with the control group, the observation group had significantly decreased MAP at T1 to T4 and HR at T1 to T3 (P<0.05). Compared with that at T0, MAP was significantly increased at T1 to T4 in the control group and at T3 in the observation group (P<0.05). HR was significantly higher at T1 to T3 than at T0 (P<0.05). Compared with the control group, the observation group showed significantly lower intraoperative Ppeak value, incidence of intraoperative adverse reactions, and postoperative agitation score, significantly shorter examination time, and better effects of amnesia and anesthesia (P<0.05). There was no significant difference in the degree of intraoperative sedation and postoperative awakening time between the two groups (P>0.05). Conclusions Dexmedetomidine hydrochloride combined with midazolam is a safe and effective way to administer general anesthesia for fiberoptic bronchoscopy in children, which can ensure stable vital signs during examination, reduce intraoperative adverse reactions and postoperative agitation, shorten examination time, and increase amnesic effect.
ZHANG Jin,LIU Jie-Bo,ZENG Fen-Na et al. Safety and efficacy of dexmedetomidine hydrochloride combined with midazolam in fiberoptic bronchoscopy in children: a prospective randomized controlled study[J]. CJCP, 2021, 23(10): 981-986.
Yin WC, Wang CY, Peng Y, et al. Dexmedetomidine alleviates H2O2-induced oxidative stress and cell necroptosis through activating of α2-adrenoceptor in H9C2 cells[J]. Mol Biol Rep, 2020, 47(5): 3629-3639. PMID: 32342432. DOI: 10.1007/s11033-020-05456-w.
Li ZB, Li GC, Qin J. Dexmedetomidine attenuates lung injury in toxic shock rats by inhibiting inflammation and autophagy[J]. Arch Med Res, 2021, 52(3): 277-283. PMID: 33248818. DOI: 10.1016/j.arcmed.2020.11.001.
Wu ZF, He L, Lai Y, et al. Observation of the sedative effect of dexmedetomidine combined with midazolam nasal drops before a pediatric craniocerebral MRI[J]. J Craniofac Surg, 2020, 31(6): 1796-1799. PMID: 32877157. DOI: 10.1097/SCS.0000000000006657.
van Groen BD, Krekels EHJ, Mooij MG, et al. The oral bioavailability and metabolism of midazolam in stable critically ill children: a pharmacokinetic microtracing study[J]. Clin Pharmacol Ther, 2021, 109(1): 140-149. PMID: 32403162. PMCID: PMC7818442. DOI: 10.1002/cpt.1890.
